Royalty Pharma plc Business Acquisition, Pro Forma Revenue
Royalty Pharma plc (RPRX) reported Business Acquisition, Pro Forma Revenue of $2.38 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2026-08-05
- Royalty Pharma plc business acquisition, pro forma revenue for the quarter ending 2025-12-31 was $621.99M, a 4.78% increase year-over-year.
- Royalty Pharma plc business acquisition, pro forma revenue for the quarter ending 2025-09-30 was $609.29M, a 7.90% increase year-over-year.
- Royalty Pharma plc business acquisition, pro forma revenue for the quarter ending 2025-06-30 was $578.66M, a 7.71% increase year-over-year.
- Royalty Pharma plc business acquisition, pro forma revenue for the quarter ending 2024-12-31 was $593.64M.
- Royalty Pharma plc business acquisition, pro forma revenue for fiscal 2025 was $2.38B, a 5.06% increase from fiscal 2024.
- Royalty Pharma plc business acquisition, pro forma revenue for fiscal 2024 was $2.26B.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|
| 2025-12-31 | $621.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.23B derived: sum of 2 quarters · filed 2026-02-11 | $1.81B derived: sum of 3 quarters · filed 2026-08-05 | $2.38B 10-K · filed 2026-02-11 |
| 2025-09-30 | $609.29M 10-Q · filed 2025-11-05 | $1.19B derived: sum of 2 quarters · filed 2026-08-05 | $1.76B 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $578.66M 10-Q · filed 2026-08-05 | $1.15B 10-Q · filed 2026-08-05 | ||
| 2024-12-31 | $593.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.16B derived: sum of 2 quarters · filed 2026-02-11 | $1.70B derived: sum of 3 quarters · filed 2026-02-11 | $2.26B 10-K · filed 2026-02-11 |
| 2024-09-30 | $564.69M 10-Q · filed 2025-11-05 | $1.10B derived: sum of 2 quarters · filed 2025-11-05 | $1.67B 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $537.27M 10-Q · filed 2025-08-06 | $1.11B 10-Q · filed 2025-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |